87a582d2-22f0-4d22-8d2d-8fec2f1e7e8f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- KRAS_SIGNALING_UP+0.400
- MYOGENESIS+0.400
- APICAL_JUNCTION+0.300
- COAGULATION+0.300
- HEDGEHOG_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
- XENOBIOTIC_METABOLISM+0.300
- ADIPOGENESIS+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- INTERFERON_ALPHA_RESPONSE-0.500
- MYC_TARGETS_V1-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- DNA_REPAIR-0.300
- E2F_TARGETS-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- G2M_CHECKPOINT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-6227-01A-11R-1915-07 | — | — | 0.882 |
| 2 | TCGA-BH-A0BP-01A-11R-A115-07 | — | A | 0.867 |
| 3 | SRR8613790 | — | A | 0.860 |
| 4 | 3d97737f-01a1-43f1-ba35-ee7cc84dc7ff | — | — | 0.859 |
| 5 | ERR2208943 | — | — | 0.859 |
| 6 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.840 |
| 7 | ERR4976601 | — | E | 0.838 |
| 8 | SRR5088898 | — | — | 0.834 |
| 9 | SRR8518203 | — | A | 0.830 |
| 10 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |